Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?
Crossref DOI link: https://doi.org/10.1007/s40273-014-0238-7
Published Online: 2014-11-26
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McDonald, Heather
Charles, Cathy
Elit, Laurie
Gafni, Amiram
Text and Data Mining valid from 2014-11-26